



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Medicare Part D - Gleevec (imatinib)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Form with fields for Patient Name, Prescriber Name, Supervising Physician, Member/Subscriber Number, Date of Birth, Group Number, Address, City, State ZIP, Primary Phone, Fax, Office Contact, NPI, Address, City, State ZIP, Specialty/facility name, Phone, and State Lic ID.

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Is this patient a new start?
Q2. For what diagnosis is this drug being prescribed (pick one)?
Q3. Please provide ICD code(s) for diagnosis
Q4. If CML, what phase is the disease in?



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Medicare Part D - Gleevec (imatinib)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:
	Supervising Physician:
<input type="checkbox"/> Chronic Phase <input type="checkbox"/> Blast Crisis <input type="checkbox"/> Accelerated Phase	
Q5. If CML, is the patient newly diagnosed? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q6. If CML and not newly diagnosed, has the patient failed interferon-alpha therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q7. If ALL, does the patient have relapsed or refractory disease? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q8. If MDS/MPD, does the patient have PDGFR (platelet-derived growth factor receptor) gene re-arrangements? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q9. If ASM, does the patient have the D816V c-Kit mutation or is the c-Kit mutational status unknown? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q10. If HES and/or CEL, is the FIP1L1-PDGFR alpha fusion kinase negative or unknown? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q11. If DFSP, is the disease unresectable, recurrent and/or metastatic? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q12. If GIST, is the tumor unresectable and/or metastatic? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q13. If GIST, if the tumor has been resected, is this being used as adjuvant treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q14. Is the prescribing physician a hematologist or oncologist? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q15. Additional Comments	



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Medicare Part D - Gleevec (imatinib)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:

Prescriber Signature

Date

Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document